Ezh2
Mostrando 1-12 de 23 artigos, teses e dissertações.
-
1. Expressão da proteína EZH2 e resposta tumoral à quimioterapia neoadjuvante no câncer de mama localmente avançado
Resumo Introdução A quimioterapia neoadjuvante é o tratamento padrão para os cânceres de mama localmente avançados. Entretanto, apenas uma porcentagem desses tumores irá responder ao tratamento, devido a características histológicas e moleculares. A proteína EZH2 (enhancer of zest homolog 2) é uma histona metiltransferase associada a tumores mal
Rev. Bras. Ginecol. Obstet.. Publicado em: 2016-06
-
2. PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway
PCI-24781 is a novel histone deacetylase inhibitor that inhibits tumor proliferation and promotes cell apoptosis. However, it is unclear whether PCI-24781 inhibits Enhancer of Zeste 2 (EZH2) expression in malignant gliomas. In this work, three glioma cell lines were incubated with various concentrations of PCI-24781 (0, 0.25, 0.5, 1, 2.5 and 5 M) and analyze
Genet. Mol. Biol.. Publicado em: 21/10/2014
-
3. Avaliação da expressão da proteína EZH2 na resposta do carcinoma de mama localmente avançado à quimioterapia neoadjuvante / EZH2 protein expression on the response to neoadjuvant chemotherapy in locally advanced breast cancer
INTRODUÇÃO: O tratamento de escolha do carcinoma de mama localmente avançado é a quimioterapia neoadjuvante, porém, em virtude da heterogeneidade tumoral, sabe-se que nem todos os tumores responderão a esse tratamento. Neste contexto, avaliamos a proteína EZH2 (Enhancer of Zest Homolog 2), uma histona-metiltransferase catalisadora da trimetilação da
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 23/10/2012
-
4. BCR-ABL-mediated regulation of SH3BGRL2, D53, PRAME, DAP12 e Calcineurin A beta and biological consequences of this regulation on CML. / Regulação da expressão de SH3BGRL2, D53, PRAME, DAP12 e calcineurina A beta por BCR-ABL e consequências biológicas dessa regulação na LMC.
TRAIL was shown to selectively kill tumor cells. Not surprisingly, TRAIL is down-regulated in a variety of tumor cells, but the mechanism responsible for TRAIL inhibition remains elusive. Because TRAIL can be regulate by retinoic acid; PRAME was shown to inhibit transcription of retinoic acid receptor target genes through the polycomb protein EZH2; and we ha
Publicado em: 2009
-
5. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
Recent experiments have demonstrated that the Polycomb group (PcG) gene EZH2 is highly expressed in metastatic prostate cancer and in lymphomas. EZH2 is a component of the PRC2 histone methyltransferase complex, which also contains EED and SUZ12 and is required for the silencing of HOX gene expression during embryonic development. Here we demonstrate that bo
Oxford University Press.
-
6. Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia
The Polycomb group protein enhancer of zeste homolog 2 (EZH2), which has roles during development of numerous tissues, is a critical regulator of cell type identity. Overexpression of EZH2 has been detected in invasive breast carcinoma tissue samples and is observed in human breast tissue samples of morphologically normal lobules up to 12 years before the de
American Society for Investigative Pathology.
-
7. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. Here we investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression. EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with norma
National Academy of Sciences.
-
8. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation
The Ezh2 protein endows the Polycomb PRC2 and PRC3 complexes with histone lysine methyltransferase (HKMT) activity that is associated with transcriptional repression. We report that Ezh2 expression was developmentally regulated in the myotome compartment of mouse somites and that its down-regulation coincided with activation of muscle gene expression and dif
Cold Spring Harbor Laboratory Press.
-
9. The Polycomb-Group Gene Ezh2 Is Required for Early Mouse Development
Polycomb-group (Pc-G) genes are required for the stable repression of the homeotic selector genes and other developmentally regulated genes, presumably through the modulation of chromatin domains. Among the Drosophila Pc-G genes, Enhancer of zeste [E(z)] merits special consideration since it represents one of the Pc-G genes most conserved through evolution.
American Society for Microbiology.
-
10. Point Mutations in the WD40 Domain of Eed Block Its Interaction with Ezh2
The Polycomb group proteins are involved in maintenance of the silenced state of several developmentally regulated genes. These proteins form large aggregates with different subunit compositions. To explore the nature of these complexes and their function, we used the full-length Eed (embryonic ectoderm development) protein, a mammalian homolog of the Drosop
American Society for Microbiology.
-
11. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity
SUZ12 is a recently identified Polycomb group (PcG) protein, which together with EZH2 and EED forms different Polycomb repressive complexes (PRC2/3). These complexes contain histone H3 lysine (K) 27/9 and histone H1 K26 methyltransferase activity specified by the EZH2 SET domain. Here we show that mice lacking Suz12, like Ezh2 and Eed mutant mice, are not vi
Nature Publishing Group.
-
12. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
The polycomb repressive complex (PRC) 2 contains 3 core proteins, EZH2, SUZ12, and EED, in which the SET (suppressor of variegation–enhancer of zeste-trithorax) domain of EZH2 mediates the histone methyltransferase activity. This induces trimethylation of lysine 27 on histone H3, regulates the expression of HOX genes, and promotes proliferation and aggress
American Society of Hematology.